Abstract | PURPOSE: METHODS:
Cisplatin (50 mg/m(2), intravenously on day 1) and S-1 (80-120 mg/m(2), orally twice a day between days 1 and 14) were administered every 21 days for 6 cycles in patients with advanced or recurrent uterine cervical cancer. RESULTS: A total of 10 patients were enrolled in this trial. A total of 46 treatment cycles (median 6; range 1-6) were administered. All grade 3 or 4 hematologic toxicities were recorded in the 6 patients: 2 patients experienced anemia, 5 experienced neutropenia, 1 experienced thrombocytopenia, and 2 experienced febrile neutropenia. All grade 3 non-hematologic toxicities were recorded in the 6 patients, and no grade 4 non-hematologic toxicities occurred; the most frequent toxicities were hyponatremia in 3 patients, diarrhea in 2 patients, and infection in 2 patients. The patients with grade 3 diarrhea had received prior radiotherapy. All the patients recovered from the toxicities after receiving appropriate supportive care, and no treatment-related deaths occurred. Five patients (50 %) achieved a partial response, and 1 patient (10 %) had a stable disease. CONCLUSION:
|
Authors | Mayu Yunokawa, Noriyuki Katsumata, Harukaze Yamamoto, Makoto Kodaira, Kan Yonemori, Chikako Shimizu, Masashi Ando, Kenji Tamura, Yasuhiro Fujiwara |
Journal | Cancer chemotherapy and pharmacology
(Cancer Chemother Pharmacol)
Vol. 71
Issue 5
Pg. 1369-74
(May 2013)
ISSN: 1432-0843 [Electronic] Germany |
PMID | 23558943
(Publication Type: Clinical Trial, Journal Article)
|
Chemical References |
- Drug Combinations
- S 1 (combination)
- Tegafur
- Oxonic Acid
- Cisplatin
|
Topics |
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(administration & dosage, adverse effects, therapeutic use)
- Cisplatin
(administration & dosage)
- Combined Modality Therapy
- Dose-Response Relationship, Drug
- Drug Combinations
- Feasibility Studies
- Female
- Humans
- Middle Aged
- Neoplasm Metastasis
- Neoplasm Recurrence, Local
- Oxonic Acid
(administration & dosage)
- Pilot Projects
- Tegafur
(administration & dosage)
- Treatment Outcome
- Uterine Cervical Neoplasms
(drug therapy, pathology, radiotherapy)
|